BR0011804A - Plasmìdeo contendo um promotor firmemente regulado, célula hospedeira bacteriana, método para produzir uma pal lipidada recombinante, composição antigênica, e, método para imunizar contra uma bactéria gram-negativa - Google Patents

Plasmìdeo contendo um promotor firmemente regulado, célula hospedeira bacteriana, método para produzir uma pal lipidada recombinante, composição antigênica, e, método para imunizar contra uma bactéria gram-negativa

Info

Publication number
BR0011804A
BR0011804A BR0011804-4A BR0011804A BR0011804A BR 0011804 A BR0011804 A BR 0011804A BR 0011804 A BR0011804 A BR 0011804A BR 0011804 A BR0011804 A BR 0011804A
Authority
BR
Brazil
Prior art keywords
host cell
negative bacteria
plasmid containing
regulated promoter
antigenic composition
Prior art date
Application number
BR0011804-4A
Other languages
English (en)
Other versions
BR0011804B1 (pt
Inventor
Benjamin J Metcalf
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR0011804A publication Critical patent/BR0011804A/pt
Publication of BR0011804B1 publication Critical patent/BR0011804B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PLASMìDEO CONTENDO UM PROMOTOR FIRMEMENTE REGULADO, CéLULA HOSPEDEIRA BACTERIANA, MéTODO PARA PRODUZIR UMA PAL LIPIDADA RECOMBINANTE, COMPOSIçãO ANTIGêNICA, E, MéTODO PARA IMUNIZAR CONTRA UMA BACTéRIA GRAM-NEGATIVA". A expressão de forma lipidada de proteína associada a peptidoglicano (PAL) de bactérias gram-negativas é obtida através do uso de um plasmídeo contendo um promotor firmemente regulado. Uma célula hospedeira bacteriana é transformada, transduzida ou transfectada com tal plasmídeo. A célula hospedeira é então cultivada sob condições como que PAL recombinante lipidada é expressa. PAL recombinante lipidada é incluída em uma composição antigênica administrada par um hospedeiro mamífero imunizar contra uma bactéria gram-negativa.
BRPI0011804-4A 1999-06-25 2000-06-20 plasmìdeo contendo um promotor, célula hospedeira bacteriana, e, método para produzir uma proteìna p6 lipidada recombinante de h. influenzae. BR0011804B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14106199P 1999-06-25 1999-06-25
PCT/US2000/017020 WO2001000790A1 (en) 1999-06-25 2000-06-20 Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria

Publications (2)

Publication Number Publication Date
BR0011804A true BR0011804A (pt) 2002-03-19
BR0011804B1 BR0011804B1 (pt) 2011-11-01

Family

ID=22493991

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011804-4A BR0011804B1 (pt) 1999-06-25 2000-06-20 plasmìdeo contendo um promotor, célula hospedeira bacteriana, e, método para produzir uma proteìna p6 lipidada recombinante de h. influenzae.

Country Status (15)

Country Link
US (2) US7452715B1 (pt)
EP (1) EP1192242B1 (pt)
JP (1) JP4660043B2 (pt)
KR (1) KR100833364B1 (pt)
CN (1) CN1192101C (pt)
AT (1) ATE466928T1 (pt)
AU (1) AU782566B2 (pt)
BR (1) BR0011804B1 (pt)
CA (1) CA2370887A1 (pt)
DE (1) DE60044352D1 (pt)
DK (1) DK1192242T3 (pt)
ES (1) ES2343304T3 (pt)
IL (1) IL146895A0 (pt)
MX (1) MXPA01013253A (pt)
WO (1) WO2001000790A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425855A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
EP1746103A1 (en) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunctional protein anchors
WO2008105142A1 (ja) * 2007-02-28 2008-09-04 Nec Corporation マトリックス溶液
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8658176B2 (en) 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CN103468704B (zh) * 2012-11-06 2015-01-07 中山大学 肽聚糖结合蛋白BjApextrin2及其基因、生产方法和应用
CN102925447B (zh) * 2012-11-06 2014-04-02 中山大学 肽聚糖结合蛋白BjApextrin1及其基因、生产方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
JPH11507532A (ja) * 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
ES2337027T3 (es) * 1997-12-05 2010-04-20 Europaisches Laboratorium Fur Molekularbiologie (Embl) Nuevo metodo de clonacion de dna basado en el sistema de recombinacion rece-rect de e. coli.

Also Published As

Publication number Publication date
KR100833364B1 (ko) 2008-05-28
WO2001000790A1 (en) 2001-01-04
KR20020039270A (ko) 2002-05-25
EP1192242A1 (en) 2002-04-03
DK1192242T3 (da) 2010-07-26
US7741076B2 (en) 2010-06-22
CN1358227A (zh) 2002-07-10
IL146895A0 (en) 2002-08-14
AU782566B2 (en) 2005-08-11
BR0011804B1 (pt) 2011-11-01
CA2370887A1 (en) 2001-01-04
CN1192101C (zh) 2005-03-09
WO2001000790A9 (en) 2009-12-23
JP2003503043A (ja) 2003-01-28
AU5753400A (en) 2001-01-31
US7452715B1 (en) 2008-11-18
JP4660043B2 (ja) 2011-03-30
MXPA01013253A (es) 2002-06-04
ES2343304T3 (es) 2010-07-28
EP1192242B1 (en) 2010-05-05
DE60044352D1 (de) 2010-06-17
ATE466928T1 (de) 2010-05-15
US20090060952A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
BR0011804A (pt) Plasmìdeo contendo um promotor firmemente regulado, célula hospedeira bacteriana, método para produzir uma pal lipidada recombinante, composição antigênica, e, método para imunizar contra uma bactéria gram-negativa
AU2278497A (en) Novel non-pyrogenic bacterial strains and use of the same
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
IL98957A0 (en) Immunotherapy with interleukin-7
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
CO5680455A2 (es) Composiciones de vacuna de neisserial que comprende una com binacion de antigenos
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
PT991761E (pt) Mutantes novos de bactérias gram negativas das mucosas e a sua aplicação em vacinas.
AU7392296A (en) Dendritic cell stimulatory factor
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
AU1116400A (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
AU7467996A (en) Method of suspending inclusions
EP0722338A4 (en) PROTEIN OR PEPTIDE COCHLEATE VACCINES AND IMMUNIZATION METHODS USING THE SAME
BR9815713A (pt) Método para aumento e reparo de defeitos de tecido dérmico, subcutâneo e das cordas vocais
DE69533102D1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
Böcking et al. Ecdysteroid biosynthesis in moulting glands of the crayfish Orconectes limosus: evidence for the synthesis of 3-dehydroecdysone by in vitro synthesis and conversion studies
WO2022026896A3 (en) Sars-cov-2 receptor binding domain in native outer membrane vesicles
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering
IL110554A0 (en) Oxygenaceous skin preparations and their preparation
AU3980595A (en) Composition containing pooled transferrins as an active principle for the induction of immune tolerance against antigens
BG101174A (en) Method for the preparation of hyperimmune, heterologous serum against colienterotoxicoses in pigs and calves

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2259 DE 22-04-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.